Free Trial
NASDAQ:ZURA

Zura Bio (ZURA) Stock Price, News & Analysis

Zura Bio logo
$2.73 -0.20 (-6.83%)
(As of 11/22/2024 ET)

About Zura Bio Stock (NASDAQ:ZURA)

Key Stats

Today's Range
$2.71
$2.97
50-Day Range
$2.73
$4.92
52-Week Range
$2.00
$6.35
Volume
521,884 shs
Average Volume
363,091 shs
Market Capitalization
$178.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.80
Consensus Rating
Buy

Company Overview

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Zura Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

ZURA MarketRank™: 

Zura Bio scored higher than 78% of companies evaluated by MarketBeat, and ranked 263rd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zura Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zura Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zura Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Zura Bio are expected to decrease in the coming year, from ($0.65) to ($0.87) per share.

  • Price to Book Value per Share Ratio

    Zura Bio has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zura Bio's valuation and earnings.
  • Percentage of Shares Shorted

    4.14% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Zura Bio has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Zura Bio does not currently pay a dividend.

  • Dividend Growth

    Zura Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.14% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Zura Bio has recently decreased by 6.91%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Zura Bio has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Zura Bio this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zura Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,187.00 in company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zura Bio's insider trading history.
Receive ZURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter.

ZURA Stock News Headlines

Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab
Research Analysts Set Expectations for Zura Bio Q3 Earnings
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Zura Bio Limited: Q3 2024 Financial Insights and Strategic Progress
Zura Bio initiated with an Outperform at Leerink
See More Headlines

ZURA Stock Analysis - Frequently Asked Questions

Zura Bio's stock was trading at $4.67 on January 1st, 2024. Since then, ZURA shares have decreased by 41.5% and is now trading at $2.73.
View the best growth stocks for 2024 here
.

Zura Bio Limited (NASDAQ:ZURA) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.12.

Top institutional investors of Zura Bio include Great Point Partners LLC (4.86%), Braidwell LP (3.68%), Geode Capital Management LLC (1.36%) and Sphera Funds Management LTD. (1.10%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell and Kiran Nistala.
View institutional ownership trends
.

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS).

Company Calendar

Last Earnings
11/07/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZURA
Web
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.80
High Stock Price Target
$26.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+478.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-69,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.37 per share

Miscellaneous

Free Float
50,864,000
Market Cap
$178.25 million
Optionable
Optionable
Beta
0.14
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:ZURA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners